The University of Chicago Header Logo

Connection

David T. Rubin to Humans

Back to Details
This is a "connection" page, showing publications David T. Rubin has written about Humans.
David T. Rubin
Connection Strength
4.889
Humans
  1. Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study. J Manag Care Spec Pharm. 2024 Nov; 30(11):1276-1287.
    View in: PubMed
    Score: 0.032
  2. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflamm Bowel Dis. 2024 Oct 03; 30(10):1776-1787.
    View in: PubMed
    Score: 0.032
  3. An Insight into Patients' Perspectives of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts. Inflamm Bowel Dis. 2024 Oct 03; 30(10):1748-1758.
    View in: PubMed
    Score: 0.032
  4. Impact of a health-system specialty pharmacy on time to upadacitinib initiation. Am J Health Syst Pharm. 2024 Sep 23; 81(19):e594-e600.
    View in: PubMed
    Score: 0.032
  5. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. BMC Gastroenterol. 2024 Sep 17; 24(1):314.
    View in: PubMed
    Score: 0.032
  6. The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative Colitis. Inflamm Bowel Dis. 2024 Jun 03; 30(6):939-949.
    View in: PubMed
    Score: 0.031
  7. Utility of the Endoscopic Healing Index in Identifying Active Inflammation in Patients with Crohn's Disease: Real World Data from a Tertiary Center. Dig Dis Sci. 2024 Aug; 69(8):2955-2960.
    View in: PubMed
    Score: 0.031
  8. Overview to Challenges in IBD 2024-2029. Inflamm Bowel Dis. 2024 May 23; 30(Supplement_2):S1-S4.
    View in: PubMed
    Score: 0.031
  9. Endoscopy in Inflammatory Bowel Disease: Indications, Timing, and Biopsy Protocol. Gastrointest Endosc Clin N Am. 2025 Jan; 35(1):1-18.
    View in: PubMed
    Score: 0.031
  10. Ozanimod-exposed Patients with Ulcerative Colitis Undergoing Total Colectomy Exhibit Unique Lymph Node Histological Changes. J Crohns Colitis. 2024 Apr 23; 18(4):638-641.
    View in: PubMed
    Score: 0.031
  11. The Management of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2024 Jun; 22(6):1181-1185.
    View in: PubMed
    Score: 0.031
  12. Clinical Application of Intestinal Ultrasound in Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2024 Feb; 26(2):31-40.
    View in: PubMed
    Score: 0.030
  13. Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2023 Dec 30; 17(12):2012-2025.
    View in: PubMed
    Score: 0.030
  14. Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease. Dig Dis Sci. 2024 Feb; 69(2):355-359.
    View in: PubMed
    Score: 0.030
  15. Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.
    View in: PubMed
    Score: 0.030
  16. Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2024 Jun; 22(6):1336-1338.e2.
    View in: PubMed
    Score: 0.030
  17. At-home Disease Monitoring by Patient-performed Intestinal Ultrasound in Severe Ulcerative Colitis. Inflamm Bowel Dis. 2023 Dec 05; 29(12):1997-1998.
    View in: PubMed
    Score: 0.030
  18. Common Instances of Low-value Care in Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2024 May; 22(5):923-932.
    View in: PubMed
    Score: 0.030
  19. Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023 10 03; 29(10):1658-1661.
    View in: PubMed
    Score: 0.030
  20. (Re)Appraising Remission in Ulcerative Colitis. Inflamm Bowel Dis. 2023 08 01; 29(8):1317-1326.
    View in: PubMed
    Score: 0.029
  21. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience. Clin Gastroenterol Hepatol. 2023 07; 21(7):1913-1923.e2.
    View in: PubMed
    Score: 0.029
  22. Assessment of the Degree of Variation of Histologic Inflammation in Ulcerative Colitis. Inflamm Bowel Dis. 2023 02 01; 29(2):222-227.
    View in: PubMed
    Score: 0.028
  23. Treat-to-target and sequencing therapies in Crohn's disease. United European Gastroenterol J. 2022 12; 10(10):1121-1128.
    View in: PubMed
    Score: 0.028
  24. Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes. Dig Dis Sci. 2023 04; 68(4):1464-1472.
    View in: PubMed
    Score: 0.028
  25. A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. Inflamm Bowel Dis. 2022 10 03; 28(10):1549-1554.
    View in: PubMed
    Score: 0.028
  26. Endoscopic Management of Colitis-Associated Neoplasia. Gastrointest Endosc Clin N Am. 2022 Oct; 32(4):863-873.
    View in: PubMed
    Score: 0.028
  27. Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch-Anal Anastomosis in Pediatric Ulcerative Colitis. Inflamm Bowel Dis. 2022 09 01; 28(9):1386-1394.
    View in: PubMed
    Score: 0.028
  28. Self-Reported Failure to Address Sexual Function in Patients With Inflammatory Bowel Disease by Gastroenterologists: Barriers and Areas for Improvement. Inflamm Bowel Dis. 2022 09 01; 28(9):1465-1468.
    View in: PubMed
    Score: 0.028
  29. Diagnostic and Management Considerations for the IPAA With Crohn's Disease-Like Features. Dis Colon Rectum. 2022 12 01; 65(S1):S77-S84.
    View in: PubMed
    Score: 0.027
  30. Ileal Desmoid Tumor in Ileal Crohn's: Coincidence or Connection? Dig Dis Sci. 2023 03; 68(3):1071-1073.
    View in: PubMed
    Score: 0.027
  31. Upadacitinib Is Safe and Effective for Crohn's Disease: Real-World Data from a Tertiary Center. Dig Dis Sci. 2023 02; 68(2):385-388.
    View in: PubMed
    Score: 0.027
  32. IL-23 Monoclonal Antibodies for IBD: So Many, So Different? J Crohns Colitis. 2022 May 11; 16(Supplement_2):ii42-ii53.
    View in: PubMed
    Score: 0.027
  33. Intestinal Cancer and Dysplasia in Crohn's Disease. Gastroenterol Clin North Am. 2022 06; 51(2):369-379.
    View in: PubMed
    Score: 0.027
  34. Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2023 08; 21(9):2407-2409.e2.
    View in: PubMed
    Score: 0.027
  35. Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia. Inflamm Bowel Dis. 2022 03 30; 28(4):553-559.
    View in: PubMed
    Score: 0.027
  36. Histopathology of Colectomy Specimens Predicts Endoscopic Pouch Phenotype in Patients with Ulcerative Colitis. Dig Dis Sci. 2022 08; 67(8):4020-4031.
    View in: PubMed
    Score: 0.027
  37. Entering the Era of Disease Modification in Inflammatory Bowel Disease. Gastroenterology. 2022 04; 162(5):1367-1369.
    View in: PubMed
    Score: 0.027
  38. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 2022 01; 7(1):17-27.
    View in: PubMed
    Score: 0.026
  39. International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey. Inflamm Bowel Dis. 2021 11 15; 27(12):1942-1953.
    View in: PubMed
    Score: 0.026
  40. Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. Aliment Pharmacol Ther. 2022 02; 55(3):302-310.
    View in: PubMed
    Score: 0.026
  41. Ulcerative Colitis Patients Have Reduced Rectal Compliance Compared With Non-Inflammatory Bowel Disease Controls. Gastroenterology. 2022 01; 162(1):331-333.e1.
    View in: PubMed
    Score: 0.026
  42. Inclusion of Under-represented Racial and Ethnic Minorities in Randomized Clinical Trials for Inflammatory Bowel Disease. Gastroenterology. 2022 01; 162(1):17-21.
    View in: PubMed
    Score: 0.026
  43. Stratifying Risks of Ileal Pouch Outcomes. Clin Gastroenterol Hepatol. 2022 07; 20(7):1620-1621.
    View in: PubMed
    Score: 0.026
  44. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology. 2021 10; 161(4):1118-1132.
    View in: PubMed
    Score: 0.026
  45. The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies. Inflamm Bowel Dis. 2021 07 27; 27(8):1201-1209.
    View in: PubMed
    Score: 0.026
  46. New targets in inflammatory bowel disease therapy: 2021. Curr Opin Gastroenterol. 2021 07 01; 37(4):357-363.
    View in: PubMed
    Score: 0.025
  47. Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians. Inflamm Bowel Dis. 2021 06 15; 27(7):1096-1106.
    View in: PubMed
    Score: 0.025
  48. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United European Gastroenterol J. 2021 06; 9(5):552-560.
    View in: PubMed
    Score: 0.025
  49. Using Wearable Biosensors to Predict Length of Stay for Patients with IBD After Bowel Surgery. Dig Dis Sci. 2022 03; 67(3):844-853.
    View in: PubMed
    Score: 0.025
  50. Endoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes. Clin Gastroenterol Hepatol. 2022 02; 20(2):293-302.e9.
    View in: PubMed
    Score: 0.025
  51. Cumulative Histologic Inflammation Predicts Colorectal Neoplasia in Ulcerative Colitis: A Validation Study. Inflamm Bowel Dis. 2021 01 19; 27(2):203-206.
    View in: PubMed
    Score: 0.025
  52. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol. 2021 01 01; 116(1):125-133.
    View in: PubMed
    Score: 0.025
  53. Stopping Clinical Trials in Inflammatory Bowel Disease During the COVID-19 Pandemic Is Not a Responsible Act. J Crohns Colitis. 2020 Dec 02; 14(12):1765-1768.
    View in: PubMed
    Score: 0.024
  54. A Tertiary Care-based Complex Care Program: Improving Care for Children With Medical Complexity. Med Care. 2020 11; 58(11):958-962.
    View in: PubMed
    Score: 0.024
  55. Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. J Crohns Colitis. 2020 Oct 05; 14(10):1345-1353.
    View in: PubMed
    Score: 0.024
  56. Coronavirus and Patients With Inflammatory Bowel Disease: Management Strategies for the Practicing Clinician. Am J Gastroenterol. 2020 10; 115(10):1566-1569.
    View in: PubMed
    Score: 0.024
  57. Quantitative Variable Assessment of Patellar Instability: An MRI-Based Study. AJR Am J Roentgenol. 2020 11; 215(5):1163-1170.
    View in: PubMed
    Score: 0.024
  58. Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate. Am J Gastroenterol. 2020 08; 115(8):1298.
    View in: PubMed
    Score: 0.024
  59. Poor Sleep Quality in Crohn's Disease Is Associated With Disease Activity and Risk for Hospitalization or Surgery. Inflamm Bowel Dis. 2020 07 17; 26(8):1251-1259.
    View in: PubMed
    Score: 0.024
  60. Black Race and Public Insurance Are Predictive of Inappropriate Evaluation of Iron Deficiency Anemia and Diarrhea. Dig Dis Sci. 2021 07; 66(7):2200-2206.
    View in: PubMed
    Score: 0.024
  61. Association of Social Distancing, Population Density, and Temperature With the Instantaneous Reproduction Number of SARS-CoV-2 in Counties Across the United States. JAMA Netw Open. 2020 07 01; 3(7):e2016099.
    View in: PubMed
    Score: 0.024
  62. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology. 2020 Jul; 159(1):350-357.
    View in: PubMed
    Score: 0.023
  63. Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology. 2020 Jul; 159(1):6-13.e6.
    View in: PubMed
    Score: 0.023
  64. Re: 18F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial. Eur J Nucl Med Mol Imaging. 2020 09; 47(10):2247.
    View in: PubMed
    Score: 0.023
  65. Periendoscopic code status. Gastrointest Endosc. 2020 02; 91(2):453.
    View in: PubMed
    Score: 0.023
  66. Inpatient Management of Inflammatory Bowel Disease-Related Complications. Clin Gastroenterol Hepatol. 2020 05; 18(6):1346-1355.
    View in: PubMed
    Score: 0.023
  67. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2020 03; 51(6):637-643.
    View in: PubMed
    Score: 0.023
  68. Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. Clin Gastroenterol Hepatol. 2020 10; 18(11):2518-2525.e1.
    View in: PubMed
    Score: 0.023
  69. Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence. Am J Gastroenterol. 2019 12; 114(12):1904-1908.
    View in: PubMed
    Score: 0.023
  70. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis. 2019 Sep 19; 13(9):1105-1110.
    View in: PubMed
    Score: 0.022
  71. Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. J Crohns Colitis. 2019 Sep 19; 13(9):1158-1162.
    View in: PubMed
    Score: 0.022
  72. Proposal to Update the Curriculum in Inflammatory Bowel Diseases for Categorical Gastroenterology Fellows. Inflamm Bowel Dis. 2019 08 20; 25(9):1443-1449.
    View in: PubMed
    Score: 0.022
  73. Follow-Up of Patients With Ulcerative Colitis and Histological Normalization. Clin Gastroenterol Hepatol. 2020 04; 18(4):987-988.e1.
    View in: PubMed
    Score: 0.022
  74. Histologic Remission in Ulcerative Colitis: Are We There Yet? Am J Gastroenterol. 2019 05; 114(5):713-715.
    View in: PubMed
    Score: 0.022
  75. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know? Gastrointest Endosc Clin N Am. 2019 Jul; 29(3):405-419.
    View in: PubMed
    Score: 0.022
  76. Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients. Dis Colon Rectum. 2019 04; 62(4):463-469.
    View in: PubMed
    Score: 0.022
  77. Discussion of Code Status in the Peri-Endoscopic Period. Am J Gastroenterol. 2019 03; 114(3):372-374.
    View in: PubMed
    Score: 0.022
  78. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019 03; 114(3):384-413.
    View in: PubMed
    Score: 0.022
  79. The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information. Inflamm Bowel Dis. 2019 02 21; 25(3):427-435.
    View in: PubMed
    Score: 0.022
  80. Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 07; 64(7):1945-1951.
    View in: PubMed
    Score: 0.022
  81. Emerging Therapies for Inflammatory Bowel Disease. Adv Ther. 2018 11; 35(11):1746-1762.
    View in: PubMed
    Score: 0.021
  82. Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2018 09 15; 24(10):2135-2141.
    View in: PubMed
    Score: 0.021
  83. Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 04; 17(5):818-823.
    View in: PubMed
    Score: 0.021
  84. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
    View in: PubMed
    Score: 0.021
  85. [Nephrotic syndrome and microhematuria in a patient with nutcracker syndrome: Report of a case and review of the literature]. Internist (Berl). 2018 06; 59(6):608-614.
    View in: PubMed
    Score: 0.021
  86. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 02; 17(3):486-493.
    View in: PubMed
    Score: 0.020
  87. Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clin Gastroenterol Hepatol. 2019 01; 17(1):205-206.
    View in: PubMed
    Score: 0.020
  88. Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply. Aliment Pharmacol Ther. 2018 05; 47(10):1423-1424.
    View in: PubMed
    Score: 0.020
  89. The use of tofacitinib in the treatment of inflammatory bowel disease. Immunotherapy. 2018 08; 10(10):837-849.
    View in: PubMed
    Score: 0.020
  90. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
    View in: PubMed
    Score: 0.020
  91. Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024.
    View in: PubMed
    Score: 0.020
  92. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018 Mar; 47(6):753-762.
    View in: PubMed
    Score: 0.020
  93. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309.
    View in: PubMed
    Score: 0.020
  94. Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors. Curr Med Res Opin. 2017 11; 33(11):1945-1953.
    View in: PubMed
    Score: 0.020
  95. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791.
    View in: PubMed
    Score: 0.019
  96. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. PLoS One. 2017; 12(4):e0175099.
    View in: PubMed
    Score: 0.019
  97. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Dig Dis Sci. 2017 04; 62(4):833-842.
    View in: PubMed
    Score: 0.019
  98. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Manag Care Spec Pharm. 2017 Aug; 23(8):859-867.
    View in: PubMed
    Score: 0.019
  99. Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay. Curr Med Res Opin. 2017 May; 33(5):837-843.
    View in: PubMed
    Score: 0.019
  100. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clin Gastroenterol Hepatol. 2017 Oct; 15(10):1557-1564.e1.
    View in: PubMed
    Score: 0.019
  101. The Crohn's and Colitis Foundation of America Survey of Inflammatory Bowel Disease Patient Health Care Access. Inflamm Bowel Dis. 2017 02; 23(2):224-232.
    View in: PubMed
    Score: 0.019
  102. Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis. Curr Med Res Opin. 2017 03; 33(3):529-536.
    View in: PubMed
    Score: 0.019
  103. Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 01; 23(1):152-157.
    View in: PubMed
    Score: 0.019
  104. Outcomes of colitis-associated dysplasia after referral from the community to a tertiary center. Gastrointest Endosc. 2016 12; 84(6):1078-1079.
    View in: PubMed
    Score: 0.019
  105. Primary Rosai-Dorfman disease of the femur. Skeletal Radiol. 2017 Jan; 46(1):129-135.
    View in: PubMed
    Score: 0.018
  106. Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis. Dig Dis Sci. 2016 10; 61(10):2972-2976.
    View in: PubMed
    Score: 0.018
  107. Home Sweet Home? Will Medical Homes Be Coming to Your Neighborhood Sometime Soon? Inflamm Bowel Dis. 2016 08; 22(8):1981-3.
    View in: PubMed
    Score: 0.018
  108. When Subjects Violate the Research Covenant: Lessons Learned from a Failed Clinical Trial of Fecal Microbiota Transplantation. Am J Gastroenterol. 2016 11; 111(11):1508-1510.
    View in: PubMed
    Score: 0.018
  109. Safety and Efficacy of Live Measles Vaccine Administered to a Crohn's Disease Patient Receiving Vedolizumab. Am J Gastroenterol. 2016 04; 111(4):577.
    View in: PubMed
    Score: 0.018
  110. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. J Crohns Colitis. 2016 Aug; 10(8):925-33.
    View in: PubMed
    Score: 0.018
  111. Vedolizumab in the treatment of Crohn's disease. Expert Rev Gastroenterol Hepatol. 2016; 10(3):283-90.
    View in: PubMed
    Score: 0.017
  112. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. Curr Gastroenterol Rep. 2016 Jan; 18(1):5.
    View in: PubMed
    Score: 0.017
  113. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci. 2015 Nov; 60(11):3408-17.
    View in: PubMed
    Score: 0.017
  114. U.S. Patients with Ulcerative Colitis Do Not Have a Decreased Risk of Diverticulosis. Inflamm Bowel Dis. 2015 Sep; 21(9):2154-7.
    View in: PubMed
    Score: 0.017
  115. Penetrating Disease, Narcotic Use, and Loop Ostomy Are Associated with Ostomy and IBD-related Complications After Ostomy Surgery in Crohn's Disease Patients. J Gastrointest Surg. 2015 Oct; 19(10):1852-61.
    View in: PubMed
    Score: 0.017
  116. Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2015 Jul; 21(7):1709-18.
    View in: PubMed
    Score: 0.017
  117. Hematochezia and a Mesenteric Mass. Gastroenterology. 2015 Jul; 149(1):e12-3.
    View in: PubMed
    Score: 0.017
  118. Using a Treat-to-Target Management Strategy to Improve the Doctor-Patient Relationship in Inflammatory Bowel Disease. Am J Gastroenterol. 2015 Sep; 110(9):1252-6.
    View in: PubMed
    Score: 0.017
  119. Can we improve on the "see one, do one, teach one" paradigm in training fellows to care for patients with inflammatory bowel disease? Inflamm Bowel Dis. 2015 Apr; 21(4):766-7.
    View in: PubMed
    Score: 0.016
  120. The rationale and growth of advanced training in inflammatory bowel disease. Gastroenterology. 2015 Apr; 148(4):696-700.
    View in: PubMed
    Score: 0.016
  121. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease. J Crohns Colitis. 2015 Apr; 9(4):312-7.
    View in: PubMed
    Score: 0.016
  122. Patchy colitis and interstitial lung disease. Gastroenterology. 2015 Jan; 148(1):26-7.
    View in: PubMed
    Score: 0.016
  123. Why it's time for updated U.S. colorectal cancer prevention guidelines in inflammatory bowel disease. Gastrointest Endosc. 2014 Nov; 80(5):849-51.
    View in: PubMed
    Score: 0.016
  124. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2014 12; 8(12):1569-81.
    View in: PubMed
    Score: 0.016
  125. Fecal microbiota transplantation: an interest in IBD? Nestle Nutr Inst Workshop Ser. 2014; 79:101-14.
    View in: PubMed
    Score: 0.016
  126. A rapid and accurate method to detect active small bowel gastrointestinal bleeding on video capsule endoscopy. Dig Dis Sci. 2014 Oct; 59(10):2503-7.
    View in: PubMed
    Score: 0.016
  127. The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2014 Jul; 24(3):353-65.
    View in: PubMed
    Score: 0.015
  128. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May; 39(10):1143-55.
    View in: PubMed
    Score: 0.015
  129. Describing the clinical phenotypes of Crohn's disease: lessons from the past: commentary on: the broadening conception of regional ileitis. Dig Dis Sci. 2014 Jan; 59(1):6-8.
    View in: PubMed
    Score: 0.015
  130. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83.
    View in: PubMed
    Score: 0.015
  131. Initial experience of a through-the-scope balloon device for ileal intubation in Crohn's disease. Gastrointest Endosc. 2013 Oct; 78(4):669-70.
    View in: PubMed
    Score: 0.015
  132. Curbing our enthusiasm for fecal transplantation in ulcerative colitis. Am J Gastroenterol. 2013 Oct; 108(10):1631-3.
    View in: PubMed
    Score: 0.015
  133. Chronic pouchitis versus recurrent Crohn's disease: a diagnostic challenge. Dig Dis Sci. 2013 Oct; 58(10):2748-50.
    View in: PubMed
    Score: 0.015
  134. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1601-8.e1-4.
    View in: PubMed
    Score: 0.015
  135. Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Inflamm Bowel Dis. 2013 Jun; 19(7):1506-13.
    View in: PubMed
    Score: 0.015
  136. What you see is not always what you get: raising the bar on clinical trial methodology in ulcerative colitis. Gastroenterology. 2013 Jul; 145(1):45-47.
    View in: PubMed
    Score: 0.015
  137. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
    View in: PubMed
    Score: 0.014
  138. Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy. J Clin Gastroenterol. 2013 Jan; 47(1):52-7.
    View in: PubMed
    Score: 0.014
  139. Colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection in a child. Am J Gastroenterol. 2012 Dec; 107(12):1930-1.
    View in: PubMed
    Score: 0.014
  140. In memoriam. Inflamm Bowel Dis. 2012 Nov; 18(11):2001-3.
    View in: PubMed
    Score: 0.014
  141. Joseph Barnett Kirsner, MD, PhD. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1181-2.
    View in: PubMed
    Score: 0.014
  142. Joseph Barnett Kirsner, MD, PhD. Dig Dis Sci. 2012 Nov; 57(11):2722-4.
    View in: PubMed
    Score: 0.014
  143. In memoriam: Dr Joseph Barnett Kirsner. Gut. 2012 Nov; 61(11):1636-7.
    View in: PubMed
    Score: 0.014
  144. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012 Dec; 18(12):2225-31.
    View in: PubMed
    Score: 0.013
  145. Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1026-32.
    View in: PubMed
    Score: 0.013
  146. Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. World J Gastroenterol. 2012 Jan 21; 18(3):197-204.
    View in: PubMed
    Score: 0.013
  147. Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. Dig Dis Sci. 2012 Jan; 57(1):250-3.
    View in: PubMed
    Score: 0.013
  148. Infectious proctitis: when to suspect it is not inflammatory bowel disease. Dig Dis Sci. 2012 Feb; 57(2):269-73.
    View in: PubMed
    Score: 0.013
  149. Total abdominal colectomy for refractory ulcerative colitis. Surgical treatment in evolution. J Gastrointest Surg. 2011 Nov; 15(11):1909-16.
    View in: PubMed
    Score: 0.013
  150. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflamm Bowel Dis. 2012 May; 18(5):818-25.
    View in: PubMed
    Score: 0.013
  151. A practical, evidence-based guide to the use of adalimumab in Crohn's disease. Curr Med Res Opin. 2011 Sep; 27(9):1803-13.
    View in: PubMed
    Score: 0.013
  152. Fecal bacteriotherapy for ulcerative colitis: patients are ready, are we? Inflamm Bowel Dis. 2012 Apr; 18(4):676-84.
    View in: PubMed
    Score: 0.013
  153. Dynamic neural networks supporting memory retrieval. Neuroimage. 2011 Jul 15; 57(2):608-16.
    View in: PubMed
    Score: 0.013
  154. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
    View in: PubMed
    Score: 0.013
  155. We once were blind and now we see: is it time to treat ulcerative colitis to achieve mucosal healing? Clin Gastroenterol Hepatol. 2011 Jun; 9(6):456-7.
    View in: PubMed
    Score: 0.012
  156. Active Crohn's disease in the small bowel: evaluation by diffusion weighted imaging and quantitative dynamic contrast enhanced MR imaging. J Magn Reson Imaging. 2011 Mar; 33(3):615-24.
    View in: PubMed
    Score: 0.012
  157. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011 Mar; 33(6):672-8.
    View in: PubMed
    Score: 0.012
  158. The peri-appendiceal red patch in ulcerative colitis: review of the University of Chicago experience. Dig Dis Sci. 2010 Dec; 55(12):3495-501.
    View in: PubMed
    Score: 0.012
  159. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010 Aug; 16(8):1352-6.
    View in: PubMed
    Score: 0.012
  160. Performance of CT colonography in clinical trials. Gastrointest Endosc Clin N Am. 2010 Apr; 20(2):193-207.
    View in: PubMed
    Score: 0.012
  161. Quality of care in inflammatory bowel disease: a review and discussion. Inflamm Bowel Dis. 2010 Jan; 16(1):125-33.
    View in: PubMed
    Score: 0.011
  162. Novel diagnostic and prognostic modalities in inflammatory bowel disease. Gastroenterol Clin North Am. 2009 Dec; 38(4):729-52.
    View in: PubMed
    Score: 0.011
  163. Do colorectal cancer patients understand that their family is at risk? Dig Dis Sci. 2009 Nov; 54(11):2473-83.
    View in: PubMed
    Score: 0.011
  164. The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci. 2010 Apr; 55(4):1044-52.
    View in: PubMed
    Score: 0.011
  165. Genetic testing for inflammatory bowel disease: focus group analysis of patients and family members. Genet Test Mol Biomarkers. 2009 Aug; 13(4):495-503.
    View in: PubMed
    Score: 0.011
  166. Association of colorectal cancer and prostate cancer and impact of radiation therapy. Cancer Epidemiol Biomarkers Prev. 2009 Jul; 18(7):1979-85.
    View in: PubMed
    Score: 0.011
  167. Positron emission tomography (PET) used to image subclinical inflammation associated with ulcerative colitis (UC) in remission. Inflamm Bowel Dis. 2009 May; 15(5):750-5.
    View in: PubMed
    Score: 0.011
  168. Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey. Inflamm Bowel Dis. 2009 Apr; 15(4):581-8.
    View in: PubMed
    Score: 0.011
  169. A rare case of granulocytic sarcoma in the mandible of a 4-year-old child: a case report and review of the literature. J Oral Maxillofac Surg. 2009 Feb; 67(2):410-6.
    View in: PubMed
    Score: 0.011
  170. Identification of patients at increased risk for colorectal cancer in an open access endoscopy center. J Clin Gastroenterol. 2008 Oct; 42(9):1025-31.
    View in: PubMed
    Score: 0.011
  171. An updated approach to dysplasia in IBD. J Gastrointest Surg. 2008 Dec; 12(12):2153-6.
    View in: PubMed
    Score: 0.010
  172. Association between colorectal cancer and urologic cancers. Arch Intern Med. 2008 May 12; 168(9):1003-9.
    View in: PubMed
    Score: 0.010
  173. Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol. 2008 May 07; 14(17):2662-9.
    View in: PubMed
    Score: 0.010
  174. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis. 2008 Feb; 14(2):265-74.
    View in: PubMed
    Score: 0.010
  175. Corynebacterium bovis line related septicemia: a case report and review of the literature. Scand J Infect Dis. 2008; 40(6-7):575-7.
    View in: PubMed
    Score: 0.010
  176. Medical professionalism and the doctor-patient relationship. Perspect Biol Med. 2008; 51(4):547-53.
    View in: PubMed
    Score: 0.010
  177. p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease. Dig Dis Sci. 2008 Feb; 53(2):474-80.
    View in: PubMed
    Score: 0.010
  178. What is the most effective way to communicate results after endoscopy? Gastrointest Endosc. 2007 Jul; 66(1):108-12.
    View in: PubMed
    Score: 0.010
  179. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007 Jun; 65(7):998-1004.
    View in: PubMed
    Score: 0.010
  180. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007 Apr; 13(4):367-71.
    View in: PubMed
    Score: 0.009
  181. Colonic infiltration with chronic myelomonocytic leukemia. Nat Clin Pract Gastroenterol Hepatol. 2007 Apr; 4(4):229-33.
    View in: PubMed
    Score: 0.009
  182. The complexity and challenges of genetic counseling and testing for inflammatory bowel disease. J Genet Couns. 2006 Dec; 15(6):465-76.
    View in: PubMed
    Score: 0.009
  183. Surveillance of dysplasia in inflammatory bowel disease: The gastroenterologist-pathologist partnership. Clin Gastroenterol Hepatol. 2006 Nov; 4(11):1309-13.
    View in: PubMed
    Score: 0.009
  184. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006 Nov; 4(11):1346-50.
    View in: PubMed
    Score: 0.009
  185. Comparison of routine and unprepped CT colonography augmented by low fiber diet and stool tagging: a pilot study. Abdom Imaging. 2007 Jan-Feb; 32(1):96-104.
    View in: PubMed
    Score: 0.009
  186. Surveillance for cancer and dysplasia in inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Sep; 35(3):581-604.
    View in: PubMed
    Score: 0.009
  187. Do patients with inflammatory bowel disease want genetic testing? Inflamm Bowel Dis. 2006 Jun; 12(6):497-502.
    View in: PubMed
    Score: 0.009
  188. The changing face of colorectal cancer in inflammatory bowel disease: progress at last! Gastroenterology. 2006 Apr; 130(4):1350-2.
    View in: PubMed
    Score: 0.009
  189. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol. 2005 Jun; 100(6):1354-6.
    View in: PubMed
    Score: 0.008
  190. Superior mesenteric vein thrombosis after colectomy in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jun; 2(6):281-5; quiz 1 p following 285.
    View in: PubMed
    Score: 0.008
  191. To test or "NOD-2" test: what are the questions? The balanced viewpoint. Inflamm Bowel Dis. 2005 May; 11(5):510-2.
    View in: PubMed
    Score: 0.008
  192. Role of antibiotics in the management of inflammatory bowel disease: a review. Rev Gastroenterol Disord. 2005; 5 Suppl 3:S10-5.
    View in: PubMed
    Score: 0.008
  193. Risk of Common Neurological Disorders in Adult Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2024 Nov 04; 30(11):2195-2204.
    View in: PubMed
    Score: 0.008
  194. Management of Colorectal Neoplasia in IBD Patients: Current Practice and Future Perspectives. J Crohns Colitis. 2024 Oct 15; 18(10):1726-1735.
    View in: PubMed
    Score: 0.008
  195. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med. 2024 Sep 26; 391(12):1119-1129.
    View in: PubMed
    Score: 0.008
  196. Development of Luminescent Biosensors for Calprotectin. ACS Chem Biol. 2024 Jun 21; 19(6):1250-1259.
    View in: PubMed
    Score: 0.008
  197. Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme. J Crohns Colitis. 2024 May 31; 18(5):695-707.
    View in: PubMed
    Score: 0.008
  198. Inflammatory bowel disease has no borders: engaging patients as partners to deliver global, equitable and holistic health care. Lancet. 2024 Aug 03; 404(10451):414-417.
    View in: PubMed
    Score: 0.008
  199. Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Crohn's Disease in US and Europe: Results from the Cross-Sectional CONFIDE Study. Dig Dis Sci. 2024 Jul; 69(7):2333-2344.
    View in: PubMed
    Score: 0.008
  200. Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD. J Crohns Colitis. 2024 Apr 23; 18(4):548-559.
    View in: PubMed
    Score: 0.008
  201. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure. Clin Gastroenterol Hepatol. 2024 Oct; 22(10):2096-2106.
    View in: PubMed
    Score: 0.008
  202. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. J Crohns Colitis. 2024 Feb 26; 18(2):264-274.
    View in: PubMed
    Score: 0.008
  203. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol. 2024 Feb; 9(2):133-146.
    View in: PubMed
    Score: 0.008
  204. Role of artificial intelligence in imaging and endoscopy for the diagnosis, monitoring and prognostication of inflammatory bowel disease: a scoping review protocol. BMJ Open Gastroenterol. 2023 12 11; 10(1).
    View in: PubMed
    Score: 0.008
  205. A Comparative Evaluation of the Measurement Properties of Three Histological Indices of Mucosal Healing in Ulcerative Colitis: Geboes Score, Robarts Histopathology Index and Nancy Index. J Crohns Colitis. 2023 Nov 24; 17(11):1733-1743.
    View in: PubMed
    Score: 0.008
  206. Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme. J Crohns Colitis. 2023 Nov 24; 17(11):1761-1770.
    View in: PubMed
    Score: 0.008
  207. Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data. Inflamm Bowel Dis. 2023 11 02; 29(11):1723-1729.
    View in: PubMed
    Score: 0.007
  208. Long-Term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data Over 8 Years From the Hong Kong FMT Registry. Clin Gastroenterol Hepatol. 2024 Mar; 22(3):611-620.e12.
    View in: PubMed
    Score: 0.007
  209. Crohn's Disease Features in Anastomotic Biopsies from Patients With and Without Crohn's Disease: Diagnostic and Prognostic Value. Mod Pathol. 2023 Nov; 36(11):100325.
    View in: PubMed
    Score: 0.007
  210. Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open. Inflamm Bowel Dis. 2023 09 01; 29(9):1370-1379.
    View in: PubMed
    Score: 0.007
  211. Treatment of Chronic Inflammatory Pouch Conditions With Tofacitinib: A Case Series From 2 Tertiary IBD Centers in the United States. Inflamm Bowel Dis. 2023 09 01; 29(9):1504-1507.
    View in: PubMed
    Score: 0.007
  212. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology. 2023 12; 165(6):1443-1457.
    View in: PubMed
    Score: 0.007
  213. Creation of an Inflammatory Bowel Disease Referral Pathway for Identifying Patients Who Would Benefit From Inflammatory Bowel Disease Specialist Consultation. Inflamm Bowel Dis. 2023 08 01; 29(8):1177-1190.
    View in: PubMed
    Score: 0.007
  214. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. Lancet Gastroenterol Hepatol. 2023 09; 8(9):853-859.
    View in: PubMed
    Score: 0.007
  215. Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions. J Crohns Colitis. 2023 Jul 05; 17(7):1066-1078.
    View in: PubMed
    Score: 0.007
  216. Transient Suppression of Bacterial Populations Associated with Gut Health is Critical in Success of Exclusive Enteral Nutrition for Children with Crohn's Disease. J Crohns Colitis. 2023 Jul 05; 17(7):1103-1113.
    View in: PubMed
    Score: 0.007
  217. Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis. Nat Med. 2023 Jun; 29(6):1520-1529.
    View in: PubMed
    Score: 0.007
  218. Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions. Am J Gastroenterol. 2023 11 01; 118(11):1940-1953.
    View in: PubMed
    Score: 0.007
  219. Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21). BMC Med Res Methodol. 2023 05 25; 23(1):129.
    View in: PubMed
    Score: 0.007
  220. Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis. Inflamm Bowel Dis. 2023 05 02; 29(5):695-704.
    View in: PubMed
    Score: 0.007
  221. Metabolic independence drives gut microbial colonization and resilience in health and disease. Genome Biol. 2023 04 17; 24(1):78.
    View in: PubMed
    Score: 0.007
  222. Ultrasonographic Transmural Healing in Crohn's Disease. Am J Gastroenterol. 2023 06 01; 118(6):961-969.
    View in: PubMed
    Score: 0.007
  223. Guide to Intestinal Ultrasound Credentialing, Documentation, and Billing for Gastroenterologists in the United States. Am J Gastroenterol. 2023 09 01; 118(9):1528-1531.
    View in: PubMed
    Score: 0.007
  224. Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Crohns Colitis. 2023 Mar 18; 17(2):199-210.
    View in: PubMed
    Score: 0.007
  225. Long-Term Outcomes of the Excluded Rectum in Crohn's Disease: A Multicenter International Study. Inflamm Bowel Dis. 2023 03 01; 29(3):417-422.
    View in: PubMed
    Score: 0.007
  226. Intestinal Ultrasound in the Assessment and Management of Inflammatory Bowel Disease: Is It Ready for Standard Practice? Gastroenterology. 2023 05; 164(6):851-855.
    View in: PubMed
    Score: 0.007
  227. Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial. Aliment Pharmacol Ther. 2023 01; 57(2):205-214.
    View in: PubMed
    Score: 0.007
  228. Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. Inflamm Bowel Dis. 2022 09 01; 28(9):1321-1331.
    View in: PubMed
    Score: 0.007
  229. Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study. Gastroenterology. 2022 12; 163(6):1555-1568.
    View in: PubMed
    Score: 0.007
  230. Hypertensive Emergency After Initiating Ozanimod: A Case Report. Inflamm Bowel Dis. 2022 08 01; 28(8):e114-e115.
    View in: PubMed
    Score: 0.007
  231. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses. Clin Gastroenterol Hepatol. 2023 08; 21(9):2211-2221.
    View in: PubMed
    Score: 0.007
  232. Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 09; 7(9):871-893.
    View in: PubMed
    Score: 0.007
  233. Serum Cytomegalovirus Polymerase Chain Reaction Test Is a Valuable Negative Predictor of Infection in Acute Severe Ulcerative Colitis. Dig Dis Sci. 2023 03; 68(3):897-901.
    View in: PubMed
    Score: 0.007
  234. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
    View in: PubMed
    Score: 0.007
  235. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 05 28; 399(10340):2015-2030.
    View in: PubMed
    Score: 0.007
  236. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022 05 28; 399(10340):2031-2046.
    View in: PubMed
    Score: 0.007
  237. Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. Lancet Gastroenterol Hepatol. 2022 05; 7(5):390-391.
    View in: PubMed
    Score: 0.007
  238. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. Lancet Gastroenterol Hepatol. 2022 07; 7(7):666-678.
    View in: PubMed
    Score: 0.007
  239. The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 11; 20(11):2427-2434.
    View in: PubMed
    Score: 0.007
  240. Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD. BMC Gastroenterol. 2022 Feb 19; 22(1):71.
    View in: PubMed
    Score: 0.007
  241. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clin Gastroenterol Hepatol. 2022 11; 20(11):2619-2627.e1.
    View in: PubMed
    Score: 0.007
  242. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology. 2022 05; 162(6):1650-1664.e8.
    View in: PubMed
    Score: 0.007
  243. What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented? Gastroenterology. 2022 04; 162(5):1396-1408.
    View in: PubMed
    Score: 0.007
  244. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. Lancet Gastroenterol Hepatol. 2022 03; 7(3):254-261.
    View in: PubMed
    Score: 0.007
  245. Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2021 12 01; 116(12):2410-2418.
    View in: PubMed
    Score: 0.007
  246. Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study. J Rheumatol. 2022 03; 49(3):320-329.
    View in: PubMed
    Score: 0.007
  247. Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95.
    View in: PubMed
    Score: 0.007
  248. Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflamm Bowel Dis. 2021 10 18; 27(10):1620-1625.
    View in: PubMed
    Score: 0.006
  249. Vedolizumab and Anti-Tumour Necrosis Factor a Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021 Oct 07; 15(10):1694-1706.
    View in: PubMed
    Score: 0.006
  250. Dissemination of Gastroenterology and Hepatology Research on Social Media Platforms Is Associated With Increased Citation Count. Am J Gastroenterol. 2021 10 01; 116(10):2137-2139.
    View in: PubMed
    Score: 0.006
  251. How to Navigate National Societal Organizations for Leadership Development and Academic Promotion: A Guide for Trainees and Young Faculty. Gastroenterology. 2021 11; 161(5):1361-1365.
    View in: PubMed
    Score: 0.006
  252. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021 12; 18(12):857-873.
    View in: PubMed
    Score: 0.006
  253. Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2021 10; 6(10):826-849.
    View in: PubMed
    Score: 0.006
  254. Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. J Crohns Colitis. 2021 Jul 05; 15(7):1130-1141.
    View in: PubMed
    Score: 0.006
  255. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. Curr Opin Gastroenterol. 2021 07 01; 37(4):313-319.
    View in: PubMed
    Score: 0.006
  256. Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. Inflamm Bowel Dis. 2021 06 15; 27(7):1008-1016.
    View in: PubMed
    Score: 0.006
  257. Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review. Expert Rev Gastroenterol Hepatol. 2021 Sep; 15(9):985-997.
    View in: PubMed
    Score: 0.006
  258. Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease: TARGET-IBD. J Clin Gastroenterol. 2022 07 01; 56(6):529-535.
    View in: PubMed
    Score: 0.006
  259. Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic: Experience and Recommendations. Mayo Clin Proc. 2021 06; 96(6):1418-1425.
    View in: PubMed
    Score: 0.006
  260. Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis. World J Gastroenterol. 2021 May 28; 27(20):2521-2530.
    View in: PubMed
    Score: 0.006
  261. Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease. J Gastroenterol Hepatol. 2021 Oct; 36(10):2785-2793.
    View in: PubMed
    Score: 0.006
  262. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2021 05 17; 27(6):947-955.
    View in: PubMed
    Score: 0.006
  263. Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey. Inflamm Bowel Dis. 2021 05 17; 27(6):836-847.
    View in: PubMed
    Score: 0.006
  264. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterol J. 2021 05; 9(4):451-460.
    View in: PubMed
    Score: 0.006
  265. Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic. JAMA Netw Open. 2021 04 01; 4(4):e216842.
    View in: PubMed
    Score: 0.006
  266. Virtual colonoscopy: a novel imaging modality for colorectal cancer. Curr Oncol Rep. 2001 Mar; 3(2):88-93.
    View in: PubMed
    Score: 0.006
  267. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 04; 160(5):1570-1583.
    View in: PubMed
    Score: 0.006
  268. The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn's Disease. Digestion. 2021; 102(5):767-775.
    View in: PubMed
    Score: 0.006
  269. How to Integrate a Medical Ethics Curriculum into Gastroenterology Fellowships. Gastroenterology. 2021 03; 160(4):1003-1006.
    View in: PubMed
    Score: 0.006
  270. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021 Apr; 70(4):635-640.
    View in: PubMed
    Score: 0.006
  271. Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 01 19; 27(2):236-241.
    View in: PubMed
    Score: 0.006
  272. Management of code status in the periendoscopic period: a national survey of current practices and beliefs of U.S. gastroenterologists. Gastrointest Endosc. 2021 07; 94(1):172-177.e2.
    View in: PubMed
    Score: 0.006
  273. COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions. Gastroenterology. 2021 04; 160(5):1447-1451.
    View in: PubMed
    Score: 0.006
  274. Evaluation of COVID-19 Testing Strategies for Repopulating College and University Campuses: A Decision Tree Analysis. J Adolesc Health. 2021 01; 68(1):28-34.
    View in: PubMed
    Score: 0.006
  275. Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. Aliment Pharmacol Ther. 2020 12; 52(11-12):1676-1682.
    View in: PubMed
    Score: 0.006
  276. Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes. Clin Gastroenterol Hepatol. 2021 11; 19(11):2444-2446.e2.
    View in: PubMed
    Score: 0.006
  277. Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic. J Crohns Colitis. 2020 Oct 21; 14(14 Suppl 3):S774-S779.
    View in: PubMed
    Score: 0.006
  278. Winter Is Coming! Clinical, Immunologic, and Practical Considerations for Vaccinating Patients With Inflammatory Bowel Disease During the Coronavirus Disease-2019 Pandemic. Gastroenterology. 2021 02; 160(3):639-644.
    View in: PubMed
    Score: 0.006
  279. Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. Clin Gastroenterol Hepatol. 2021 10; 19(10):2207-2209.e3.
    View in: PubMed
    Score: 0.006
  280. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology. 2021 01; 160(1):183-192.e3.
    View in: PubMed
    Score: 0.006
  281. Cost-effectiveness analysis of a fecal microbiota transplant center for treating recurrent C.difficile infection. J Infect. 2020 11; 81(5):758-765.
    View in: PubMed
    Score: 0.006
  282. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365.
    View in: PubMed
    Score: 0.006
  283. Restructuring Electrophysiology During the COVID-19 Pandemic: A Practical Guide From a New York City Hospital Network. Crit Pathw Cardiol. 2020 09; 19(3):105-111.
    View in: PubMed
    Score: 0.006
  284. Emerging treatment options for extraintestinal manifestations in IBD. Gut. 2021 04; 70(4):796-802.
    View in: PubMed
    Score: 0.006
  285. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Gastroenterology. 2020 12; 159(6):2052-2064.
    View in: PubMed
    Score: 0.006
  286. An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI. Clin Gastroenterol Hepatol. 2021 12; 19(12):2524-2531.
    View in: PubMed
    Score: 0.006
  287. Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 11; 19(11):2333-2342.
    View in: PubMed
    Score: 0.006
  288. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000 Aug; 12(8):855-62.
    View in: PubMed
    Score: 0.006
  289. Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.
    View in: PubMed
    Score: 0.006
  290. Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 08; 19(8):1592-1601.e3.
    View in: PubMed
    Score: 0.006
  291. Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature. Inflamm Bowel Dis. 2020 06 18; 26(7):971-973.
    View in: PubMed
    Score: 0.006
  292. Practical advice for management of inflammatory bowel diseases patients during the COVID-19 pandemic: World Endoscopy Organization Statement. Dig Endosc. 2020 Jul; 32(5):658-662.
    View in: PubMed
    Score: 0.006
  293. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment Pharmacol Ther. 2020 07; 52(1):54-72.
    View in: PubMed
    Score: 0.006
  294. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
    View in: PubMed
    Score: 0.006
  295. Performance of electrophysiology procedures at an academic medical center amidst the 2020 coronavirus (COVID-19) pandemic. J Cardiovasc Electrophysiol. 2020 06; 31(6):1249-1254.
    View in: PubMed
    Score: 0.006
  296. Policy and Practice Innovations to Improve Prescribing of Psychoactive Medications for Children. Psychiatr Serv. 2020 07 01; 71(7):706-712.
    View in: PubMed
    Score: 0.006
  297. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2021 01; 19(1):104-110.
    View in: PubMed
    Score: 0.006
  298. Impact of Physician Payments on Microvascular Breast Reconstruction: An All-Payer Claim Database Analysis. Plast Reconstr Surg. 2020 Feb; 145(2):333-339.
    View in: PubMed
    Score: 0.006
  299. Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Inflamm Bowel Dis. 2020 01 06; 26(2):304-313.
    View in: PubMed
    Score: 0.006
  300. Infliximab Does Not Promote the Presence of Collagenolytic Bacteria in a Mouse Model of Colorectal Anastomosis. J Gastrointest Surg. 2020 11; 24(11):2637-2642.
    View in: PubMed
    Score: 0.006
  301. Capsule Retention in Crohn's Disease: A Meta-analysis. Inflamm Bowel Dis. 2020 01 01; 26(1):33-42.
    View in: PubMed
    Score: 0.006
  302. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation. Inflamm Bowel Dis. 2020 01 01; 26(1):1-10.
    View in: PubMed
    Score: 0.006
  303. Exposure to Anti-tumor Necrosis Factor Medications Increases the Incidence of Pouchitis After Restorative Proctocolectomy in Patients With Ulcerative Colitis. Dis Colon Rectum. 2019 11; 62(11):1344-1351.
    View in: PubMed
    Score: 0.006
  304. Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Aug 14; 13(8):1012-1024.
    View in: PubMed
    Score: 0.006
  305. IBD-associated Colon Cancers Differ in DNA Methylation and Gene Expression Profiles Compared With Sporadic Colon Cancers. J Crohns Colitis. 2019 Jul 25; 13(7):884-893.
    View in: PubMed
    Score: 0.006
  306. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
    View in: PubMed
    Score: 0.006
  307. Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. Dig Dis Sci. 2019 12; 64(12):3596-3601.
    View in: PubMed
    Score: 0.006
  308. Challenges in IBD Research: Pragmatic Clinical Research. Inflamm Bowel Dis. 2019 05 16; 25(Suppl 2):S40-S47.
    View in: PubMed
    Score: 0.005
  309. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. J Manag Care Spec Pharm. 2019 Jul; 25(7):770-779.
    View in: PubMed
    Score: 0.005
  310. Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 07; 89:44-50.
    View in: PubMed
    Score: 0.005
  311. Renin-angiotensin system promotes colonic inflammation by inducing TH17 activation via JAK2/STAT pathway. Am J Physiol Gastrointest Liver Physiol. 2019 06 01; 316(6):G774-G784.
    View in: PubMed
    Score: 0.005
  312. Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275.
    View in: PubMed
    Score: 0.005
  313. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. 2019 12; 19(6):528-537.
    View in: PubMed
    Score: 0.005
  314. Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Gastroenterol. 2019 01; 53(1):e1-e11.
    View in: PubMed
    Score: 0.005
  315. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 01; 13(1):50-57.
    View in: PubMed
    Score: 0.005
  316. Legal Risks and Considerations Associated with Inflammatory Bowel Disease: A Primer. Am J Gastroenterol. 2018 11; 113(11):1577-1579.
    View in: PubMed
    Score: 0.005
  317. Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. Clin Gastroenterol Hepatol. 2019 08; 17(9):1673-1679.e1.
    View in: PubMed
    Score: 0.005
  318. The Influence of Physician Payments on the Method of Breast Reconstruction: A National Claims Analysis. Plast Reconstr Surg. 2018 10; 142(4):434e-442e.
    View in: PubMed
    Score: 0.005
  319. A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Aliment Pharmacol Ther. 2018 11; 48(9):933-940.
    View in: PubMed
    Score: 0.005
  320. Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: a prospective study. Gastrointest Endosc. 2018 12; 88(6):947-955.e2.
    View in: PubMed
    Score: 0.005
  321. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297.
    View in: PubMed
    Score: 0.005
  322. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis. 2018 Apr 27; 12(5):621-626.
    View in: PubMed
    Score: 0.005
  323. Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey. J Crohns Colitis. 2018 Apr 27; 12(5):600-609.
    View in: PubMed
    Score: 0.005
  324. The New Frontier: the Intestinal Microbiome and Surgery. J Gastrointest Surg. 2018 07; 22(7):1277-1285.
    View in: PubMed
    Score: 0.005
  325. Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial. PLoS One. 2018; 13(4):e0193544.
    View in: PubMed
    Score: 0.005
  326. Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology. 2018 07; 155(1):76-87.
    View in: PubMed
    Score: 0.005
  327. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. Dig Dis Sci. 2018 May; 63(5):1294-1301.
    View in: PubMed
    Score: 0.005
  328. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
    View in: PubMed
    Score: 0.005
  329. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis. 2018 Jan 24; 12(2):145-156.
    View in: PubMed
    Score: 0.005
  330. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2017 Oct 01; 11(10):1180-1199.
    View in: PubMed
    Score: 0.005
  331. Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS One. 2017; 12(8):e0182900.
    View in: PubMed
    Score: 0.005
  332. miR-4728-3p Functions as a Tumor Suppressor in Ulcerative Colitis-associated Colorectal Neoplasia Through Regulation of Focal Adhesion Signaling. Inflamm Bowel Dis. 2017 08; 23(8):1328-1337.
    View in: PubMed
    Score: 0.005
  333. Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon. Clin Gastroenterol Hepatol. 2018 Jan; 16(1):68-74.
    View in: PubMed
    Score: 0.005
  334. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Sep; 112(9):1423-1429.
    View in: PubMed
    Score: 0.005
  335. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.005
  336. miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD. Clin Cancer Res. 2017 Sep 01; 23(17):5281-5291.
    View in: PubMed
    Score: 0.005
  337. Tracking microbial colonization in fecal microbiota transplantation experiments via genome-resolved metagenomics. Microbiome. 2017 05 04; 5(1):50.
    View in: PubMed
    Score: 0.005
  338. The Drivers of Discretionary Utilization: Clinical History Versus Physician Supply. Acad Med. 2017 05; 92(5):703-708.
    View in: PubMed
    Score: 0.005
  339. Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program. Clin Pharmacol Ther. 2017 07; 102(1):106-114.
    View in: PubMed
    Score: 0.005
  340. Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis. 2017 Apr 01; 11(4):412-424.
    View in: PubMed
    Score: 0.005
  341. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis. 2017 Apr 01; 11(4):400-411.
    View in: PubMed
    Score: 0.005
  342. Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician Visits. Inflamm Bowel Dis. 2017 04; 23(4):494-501.
    View in: PubMed
    Score: 0.005
  343. Early Transcriptomic Changes in the Ileal Pouch Provide Insight into the Molecular Pathogenesis of Pouchitis and Ulcerative Colitis. Inflamm Bowel Dis. 2017 03; 23(3):366-378.
    View in: PubMed
    Score: 0.005
  344. Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther. 2017 01; 45(2):264-275.
    View in: PubMed
    Score: 0.005
  345. Patient-Specific Bacteroides Genome Variants in Pouchitis. mBio. 2016 11 15; 7(6).
    View in: PubMed
    Score: 0.005
  346. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2017 02; 15(2):229-239.e5.
    View in: PubMed
    Score: 0.005
  347. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80.
    View in: PubMed
    Score: 0.005
  348. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis. 2016 08; 22(8):1881-6.
    View in: PubMed
    Score: 0.005
  349. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Dec; 10(12):1385-1394.
    View in: PubMed
    Score: 0.004
  350. Activation of the Renin-Angiotensin System Promotes Colitis Development. Sci Rep. 2016 06 08; 6:27552.
    View in: PubMed
    Score: 0.004
  351. Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016 07; 104(1):113-20.
    View in: PubMed
    Score: 0.004
  352. Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel. Inflamm Bowel Dis. 2016 06; 22(6):1418-24.
    View in: PubMed
    Score: 0.004
  353. Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. Inflamm Bowel Dis. 2016 May; 22(5):1027-31.
    View in: PubMed
    Score: 0.004
  354. Insights into the pathogenesis of ulcerative colitis from a murine model of stasis-induced dysbiosis, colonic metaplasia, and genetic susceptibility. Am J Physiol Gastrointest Liver Physiol. 2016 06 01; 310(11):G973-88.
    View in: PubMed
    Score: 0.004
  355. Clostridium Difficile Infection in Ulcerative Colitis: Can Alteration of the Gut-associated Microbiome Contribute to Pouch Failure? Inflamm Bowel Dis. 2016 Apr; 22(4):902-11.
    View in: PubMed
    Score: 0.004
  356. Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. Inflamm Bowel Dis. 2016 Apr; 22(4):940-7.
    View in: PubMed
    Score: 0.004
  357. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7.
    View in: PubMed
    Score: 0.004
  358. Association between serrated epithelial changes and colorectal dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2016 Jul; 84(1):87-95.e1.
    View in: PubMed
    Score: 0.004
  359. Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin. Gut. 2017 02; 66(2):285-292.
    View in: PubMed
    Score: 0.004
  360. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38.
    View in: PubMed
    Score: 0.004
  361. Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States. Am J Gastroenterol. 2016 Jan; 111(1):15-23.
    View in: PubMed
    Score: 0.004
  362. Deep enteroscopy with a conventional colonoscope: initial multicenter study by using a through-the-scope balloon catheter system. Gastrointest Endosc. 2015 Nov; 82(5):855-60.
    View in: PubMed
    Score: 0.004
  363. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1919-25.
    View in: PubMed
    Score: 0.004
  364. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology. 2015 Jul; 149(1):223-37.
    View in: PubMed
    Score: 0.004
  365. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
    View in: PubMed
    Score: 0.004
  366. Chromoendoscopy for colorectal cancer surveillance in patients with inflammatory bowel disease. Curr Gastroenterol Rep. 2014 Sep; 16(9):407.
    View in: PubMed
    Score: 0.004
  367. Clinical presentation and disease course of inflammatory bowel disease differs by race in a large tertiary care hospital. Dig Dis Sci. 2014 Sep; 59(9):2228-35.
    View in: PubMed
    Score: 0.004
  368. Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2014 Jan; 20(1):14-20.
    View in: PubMed
    Score: 0.004
  369. Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis. 2013 Oct; 19(11):2440-3.
    View in: PubMed
    Score: 0.004
  370. A diagnosis that eats at you. Gastroenterology. 2013 Aug; 145(2):289, 489.
    View in: PubMed
    Score: 0.004
  371. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis. 2013 May; 19(6):1112-22.
    View in: PubMed
    Score: 0.004
  372. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013 Mar; 19(3):662-8.
    View in: PubMed
    Score: 0.004
  373. Subdural hemorrhage in pediatric patients with enlargement of the subarachnoid spaces. J Neurosurg Pediatr. 2013 Apr; 11(4):438-44.
    View in: PubMed
    Score: 0.004
  374. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb; 19(2):363-9.
    View in: PubMed
    Score: 0.004
  375. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013 Mar; 37(5):546-54.
    View in: PubMed
    Score: 0.004
  376. Screening for sleep disorders in pediatric primary care: are we there yet? Clin Pediatr (Phila). 2012 Dec; 51(12):1125-9.
    View in: PubMed
    Score: 0.004
  377. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Mar; 11(3):286-92; quiz e24.
    View in: PubMed
    Score: 0.004
  378. Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med. 2012 Jun 05; 156(11):757-66, W-260.
    View in: PubMed
    Score: 0.003
  379. Summaries for patients. Increased risk for gastrointestinal cancer in childhood cancer survivors. Ann Intern Med. 2012 Jun 05; 156(11):I-36.
    View in: PubMed
    Score: 0.003
  380. Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis. J Crohns Colitis. 2012 Aug; 6(7):756-62.
    View in: PubMed
    Score: 0.003
  381. miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis. 2012 Jan; 18(1):94-100.
    View in: PubMed
    Score: 0.003
  382. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011 Jul; 60(7):937-43.
    View in: PubMed
    Score: 0.003
  383. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11.
    View in: PubMed
    Score: 0.003
  384. When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis. 2010 Oct; 16(10):1658-62.
    View in: PubMed
    Score: 0.003
  385. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.
    View in: PubMed
    Score: 0.003
  386. Detecting colorectal cancer by 1H magnetic resonance spectroscopy of fecal extracts. NMR Biomed. 2009 Jul; 22(6):593-600.
    View in: PubMed
    Score: 0.003
  387. Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study. Acad Radiol. 2009 Oct; 16(10):1223-30.
    View in: PubMed
    Score: 0.003
  388. Israel-Gaza conflict. Lancet. 2009 Mar 14; 373(9667):891-2.
    View in: PubMed
    Score: 0.003
  389. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009 Feb 01; 29(3):247-57.
    View in: PubMed
    Score: 0.003
  390. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008 Dec; 103(12):3132-41.
    View in: PubMed
    Score: 0.003
  391. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest. 2008 Oct; 88(10):1110-20.
    View in: PubMed
    Score: 0.003
  392. Agile patency system eliminates risk of capsule retention in patients with known intestinal strictures who undergo capsule endoscopy. Gastrointest Endosc. 2008 May; 67(6):902-9.
    View in: PubMed
    Score: 0.003
  393. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm. 2008 Jan; 14(1 Suppl A):s2-12; quiz s13-5.
    View in: PubMed
    Score: 0.002
  394. Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis. Rev Gastroenterol Disord. 2008; 8(1):21-30; quiz 31-2.
    View in: PubMed
    Score: 0.002
  395. Prospective comparison of patient experience with colon imaging tests. Am J Med. 2006 Sep; 119(9):791-9.
    View in: PubMed
    Score: 0.002
  396. Inflammation's role in rectal cancer following prostate radiotherapy, and emerging evidence for a protective role for balsalazide. Gastroenterology. 2005 Aug; 129(2):770-2.
    View in: PubMed
    Score: 0.002
  397. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet. 2005 Jan 22-28; 365(9456):305-11.
    View in: PubMed
    Score: 0.002
  398. Fever and right upper quadrant pain in a pregnant woman at 30 weeks' gestation. Nat Clin Pract Gastroenterol Hepatol. 2004 Dec; 1(2):113-6; quiz 1 p following 116.
    View in: PubMed
    Score: 0.002
  399. The case: can doctors say "enough"? Camb Q Healthc Ethics. 2003; 12(2):215-23.
    View in: PubMed
    Score: 0.002
  400. Computer-aided diagnosis scheme for detection of polyps at CT colonography. Radiographics. 2002 Jul-Aug; 22(4):963-79.
    View in: PubMed
    Score: 0.002
  401. Computerized detection of colonic polyps at CT colonography on the basis of volumetric features: pilot study. Radiology. 2002 Feb; 222(2):327-36.
    View in: PubMed
    Score: 0.002
  402. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery. 2002 Jan; 131(1):6-15.
    View in: PubMed
    Score: 0.002
  403. Effects of billing and documentation requirements on the quantity and quality of teaching by attending physicians. Acad Med. 2001 Nov; 76(11):1144-7.
    View in: PubMed
    Score: 0.002
  404. Treatment of anal fissures with topical nitroglycerin. Expert Opin Pharmacother. 2001 Jan; 2(1):41-5.
    View in: PubMed
    Score: 0.002
  405. Malabsorption testing: a review. Curr Gastroenterol Rep. 2000 Oct; 2(5):370-7.
    View in: PubMed
    Score: 0.002
  406. The Montefiore community children's project: a controlled study of cognitive and emotional problems of homeless mothers and children. J Urban Health. 1999 Mar; 76(1):39-50.
    View in: PubMed
    Score: 0.001
  407. CT colonography with three-dimensional problem solving for detection of colonic polyps. AJR Am J Roentgenol. 1998 Oct; 171(4):989-95.
    View in: PubMed
    Score: 0.001
  408. Ethics of a paired-kidney-exchange program. N Engl J Med. 1997 Jun 12; 336(24):1752-5.
    View in: PubMed
    Score: 0.001
  409. Tumor angiogenesis in primary and metastatic colorectal cancers. Dis Colon Rectum. 1996 Oct; 39(10):1073-80.
    View in: PubMed
    Score: 0.001
  410. Gadolinium zeolite as an oral contrast agent for magnetic resonance imaging. J Magn Reson Imaging. 1995 Sep-Oct; 5(5):499-508.
    View in: PubMed
    Score: 0.001
  411. Reduced cardiac selenium content in the acquired immunodeficiency syndrome. JPEN J Parenter Enteral Nutr. 1989 Nov-Dec; 13(6):644-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.